The FDA granted priority-review status for Genentech's pertuzumab for treatment of breast cancer. The agency expects to finish evaluating the drug by June 8.
FDA accelerates review of Genentech breast cancer drug
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan